Feasibility of Ultrasound Microbubble Contrast-Enhanced (CEUS) Sentinel Lymph Node Imaging With Guided Biopsy in Breast Cancer Patients
Information source: M.D. Anderson Cancer Center
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Breast Cancer
Intervention: Perflutren Protein-Type A Microspheres Injectable Suspension (Drug); Contrast-Enhanced Ultrasound (CEUS) (Device); Biopsy + Radioactive Seed Placement (Procedure); Phone Call (Behavioral)
Phase: N/A
Status: Recruiting
Sponsored by: M.D. Anderson Cancer Center Official(s) and/or principal investigator(s): Basak Dogan, MD, Principal Investigator, Affiliation: M.D. Anderson Cancer Center
Overall contact: Basak Dogan, MD, Phone: 713-563-0124
Summary
The goal of this clinical research is to learn if an ultrasound contrast agent called
OPTISON (perflutren protein type A) is effective in finding sentinel lymph nodes before
surgery. Contrast agents can help make ultrasound images more accurate. The sentinel lymph
node is the first node that may be the target of cancer cells that spread from the tumor.
Clinical Details
Official title: Feasibility of Ultrasound Microbubble Contrast-Enhanced (CEUS) Ultrasound Sentinel Lymph Node Imaging With Guided Biopsy in Breast Cancer Patients
Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening
Primary outcome: Number of Breast Cancer Patients with Sentinel Lymph Nodes (SLN)
Detailed description:
Study Procedures:
If you agree and are eligible to take part, you will receive perflutren protein type A by
injection under the skin near the nipple. After you receive the injection, the radiologist
will take more ultrasound images and videos of the tumor and lymph nodes in the underarm
area.
You will have a biopsy of the sentinel lymph node that was identified in the ultrasound and
a titanium clip marker will be inserted into the node. An extra node may be removed at that
time. The clip helps distinguish the biopsied node from other nodes. You will be told the
results of biopsy. After the biopsy, a radioactive seed may be inserted into the node to
allow the surgeon to find and remove it during your surgery.
You will still have standard of care sentinel lymph node biopsy during your already
scheduled surgery. You will sign a separate surgical consent form that explains this
procedure and its risks.
You will be called by phone 30 days after the seed is removed to check for any side effects.
This phone call should take about 10 minutes.
Length of Study:
Your active participation in this study will be over the follow up phone call.
This is an investigational study. Perflutren protein type A is FDA approved and
commercially available for use in contrast-enhanced echocardiograms. Its use in this study
is investigational.
Up to 20 patients will take part in this study. All will be enrolled at MD Anderson.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Female.
Criteria:
Inclusion Criteria:
1. 18 years or older.
2. Ipsilateral biopsy-proven invasive breast cancer <5 cm in maximal dimension by
Ultrasound or Mammography.
3. No abnormal axillary nodes identified on grayscale AUS, or abnormal nodes with benign
subsequent FNA biopsy.
Exclusion Criteria:
1. Pregnant or nursing women
2. Prior SLN dissection
3. Neoadjuvant chemotherapy.
4. Prior axillary lymph node surgery.
5. Prior history of ipsilateral breast cancer.
6. Known or suspected: Cardiac shunts
7. Known or suspected: hypersensitivity to perflutren, blood, blood products or albumin
8. Known or suspected: hypersensitivity to a prior OPTISON administration
Locations and Contacts
Basak Dogan, MD, Phone: 713-563-0124
University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States; Recruiting
Additional Information
University of Texas MD Anderson Cancer Center Website
Starting date: July 2015
Last updated: July 17, 2015
|